Artículos

Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder / Vicki P Hoffmann en Journal of Clinical Psychopharmacology, Año 2010 - Vol. 30 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 656-660 Título : Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder : post hoc analyses of 3 randomized, controlled clinical trials Tipo de documento: texto impreso Autores: Vicki P Hoffmann, Autor ; Michael Case, Autor ; Virginia L. Stauffer, Autor Fecha de publicación: 2022 Artículo en la página: pp. 656-660 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Glucosa, Peso, Triglicéridos, Antipsicóticos Resumen: The objective of this study was to determine if early changes in triglycerides and weight may be useful in predicting longer-term changes in weight and other metabolic parameters. Data were from three 24- to 28-week randomized, controlled studies comparing olanzapine to ziprasidone or aripiprazole for treatment of schizophrenia. Link: ./index.php?lvl=notice_display&id=29411 [artículo] Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder : post hoc analyses of 3 randomized, controlled clinical trials [texto impreso] / Vicki P Hoffmann, Autor ; Michael Case, Autor ; Virginia L. Stauffer, Autor . - 2022 . - pp. 656-660. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 656-660 Palabras clave: Glucosa, Peso, Triglicéridos, Antipsicóticos Resumen: The objective of this study was to determine if early changes in triglycerides and weight may be useful in predicting longer-term changes in weight and other metabolic parameters. Data were from three 24- to 28-week randomized, controlled studies comparing olanzapine to ziprasidone or aripiprazole for treatment of schizophrenia. Link: ./index.php?lvl=notice_display&id=29411

Effect of fto, sh2b1, lep, and lepr polymorphisms on weight gain associated with antipsychotic treatment / Rocio Perez Iglesias en Journal of Clinical Psychopharmacology, Año 2010 - Vol. 30 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 661-666 Título : Effect of fto, sh2b1, lep, and lepr polymorphisms on weight gain associated with antipsychotic treatment Tipo de documento: texto impreso Autores: Rocio Perez Iglesias, Autor ; Ignacio Mata, Autor ; Jose Antonio Amado, Autor Fecha de publicación: 2022 Artículo en la página: pp. 661-666 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Aumento de peso, FTO, SH2B1, LEP, LEPR, Gen, Primer episodio de psicosis Resumen: Weight gain is one of the major adverse effects of antipsychotics. Although mechanisms remain unclear, genetic susceptibility has become increasingly attractive as a potential mechanism that could explain a significant part of interindividual variability. Most investigations have explored genes related with the mechanism of action of antipsychotic drugs. Link: ./index.php?lvl=notice_display&id=29412 [artículo] Effect of fto, sh2b1, lep, and lepr polymorphisms on weight gain associated with antipsychotic treatment [texto impreso] / Rocio Perez Iglesias, Autor ; Ignacio Mata, Autor ; Jose Antonio Amado, Autor . - 2022 . - pp. 661-666. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 661-666 Palabras clave: Antipsicóticos, Aumento de peso, FTO, SH2B1, LEP, LEPR, Gen, Primer episodio de psicosis Resumen: Weight gain is one of the major adverse effects of antipsychotics. Although mechanisms remain unclear, genetic susceptibility has become increasingly attractive as a potential mechanism that could explain a significant part of interindividual variability. Most investigations have explored genes related with the mechanism of action of antipsychotic drugs. Link: ./index.php?lvl=notice_display&id=29412

Association between the 1291-c/g polymorphism in the adrenergic α-2a receptor and the metabolic syndrome / Arne J. Risselada en Journal of Clinical Psychopharmacology, Año 2010 - Vol. 30 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 667-671 Título : Association between the 1291-c/g polymorphism in the adrenergic α-2a receptor and the metabolic syndrome Tipo de documento: texto impreso Autores: Arne J. Risselada, Autor ; Jelle Vehof, Autor ; Richard Bruggeman, Autor Fecha de publicación: 2022 Artículo en la página: pp. 667-671 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: ADRA2A, Antipsicóticos, Síndrome metabólico, Esquizofrenia, 1291-C/G Resumen: The prevalence of the metabolic syndrome is increased in patients with schizophrenia compared with the general population. The strong interindividual differences in susceptibility to developing the metabolic syndrome suggests that the genetic makeup is a modulating factor. Part of the genetic puzzle can possibly be explained by variations in the gene coding for the adrenergic α-2a receptor (ADRA2A) because this receptor plays an important role in lipolysis. Link: ./index.php?lvl=notice_display&id=29413 [artículo] Association between the 1291-c/g polymorphism in the adrenergic α-2a receptor and the metabolic syndrome [texto impreso] / Arne J. Risselada, Autor ; Jelle Vehof, Autor ; Richard Bruggeman, Autor . - 2022 . - pp. 667-671. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 667-671 Palabras clave: ADRA2A, Antipsicóticos, Síndrome metabólico, Esquizofrenia, 1291-C/G Resumen: The prevalence of the metabolic syndrome is increased in patients with schizophrenia compared with the general population. The strong interindividual differences in susceptibility to developing the metabolic syndrome suggests that the genetic makeup is a modulating factor. Part of the genetic puzzle can possibly be explained by variations in the gene coding for the adrenergic α-2a receptor (ADRA2A) because this receptor plays an important role in lipolysis. Link: ./index.php?lvl=notice_display&id=29413

Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults / Eric J. Lenze en Journal of Clinical Psychopharmacology, Año 2010 - Vol. 30 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 672-677 Título : Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults Tipo de documento: texto impreso Autores: Eric J. Lenze, Autor ; Alison M. Goate, Autor ; Petra Nowotny, Autor Fecha de publicación: 2022 Artículo en la página: pp. 672-677 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Geriatría, Trastornos de ansiedad, Genética, ISRS Resumen: Generalized anxiety disorder (GAD) is common in older adults and can be treated with selective serotonin reuptake inhibitors (SSRIs). Genetic variation in the serotonin transporter gene promoter region is posited to be associated with SSRI efficacy: 2 polymorphisms (5-HTTLPR S/L and rs25531 g/a) form a haplotype with the La combination having higher transcription activity than other haplotypes. Link: ./index.php?lvl=notice_display&id=29414 [artículo] Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults [texto impreso] / Eric J. Lenze, Autor ; Alison M. Goate, Autor ; Petra Nowotny, Autor . - 2022 . - pp. 672-677. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 672-677 Palabras clave: Geriatría, Trastornos de ansiedad, Genética, ISRS Resumen: Generalized anxiety disorder (GAD) is common in older adults and can be treated with selective serotonin reuptake inhibitors (SSRIs). Genetic variation in the serotonin transporter gene promoter region is posited to be associated with SSRI efficacy: 2 polymorphisms (5-HTTLPR S/L and rs25531 g/a) form a haplotype with the La combination having higher transcription activity than other haplotypes. Link: ./index.php?lvl=notice_display&id=29414

A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia / Ali Ghaleiha en Journal of Clinical Psychopharmacology, Año 2010 - Vol. 30 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 678-682 Título : A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia Tipo de documento: texto impreso Autores: Ali Ghaleiha, Autor ; Ahmad Ali Noorbala, Autor ; Farhad Farnaghi, Autor Fecha de publicación: 2022 Artículo en la página: pp. 678-682 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: 5-HT1A, Buspirona, Esquizofrenia crónica, Síntomas negativos Resumen: The role of partial agonism at 5-HT1A receptors in general and of buspirone in particular remains unclear in the treatment of negative symptoms of schizophrenia. This study was designed to investigate the effect of buspirone added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double-blind randomized clinical trial. Link: ./index.php?lvl=notice_display&id=29415 [artículo] A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia [texto impreso] / Ali Ghaleiha, Autor ; Ahmad Ali Noorbala, Autor ; Farhad Farnaghi, Autor . - 2022 . - pp. 678-682. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 678-682 Palabras clave: 5-HT1A, Buspirona, Esquizofrenia crónica, Síntomas negativos Resumen: The role of partial agonism at 5-HT1A receptors in general and of buspirone in particular remains unclear in the treatment of negative symptoms of schizophrenia. This study was designed to investigate the effect of buspirone added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double-blind randomized clinical trial. Link: ./index.php?lvl=notice_display&id=29415

Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-alzheimer's disease trial / Alette M. Wessels en Journal of Clinical Psychopharmacology, Año 2010 - Vol. 30 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 683-687 Título : Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-alzheimer's disease trial Tipo de documento: texto impreso Autores: Alette M. Wessels, Autor ; Bruce G. Pollock, Autor ; Norbert G. Anyama, Autor Fecha de publicación: 2022 Artículo en la página: pp. 683-687 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Enfermedad de Alzheimer, Suspensión del tratamiento, 9-OH risperidona Resumen: Risperidone has been used to treat behavioral symptoms, such as delusions and agitation, in people with Alzheimer's disease. The relationship between magnitude and variability of risperidone and 9-hydroxy risperidone exposure and the relationship with time to discontinuation of the medication were explored. Link: ./index.php?lvl=notice_display&id=29416 [artículo] Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-alzheimer's disease trial [texto impreso] / Alette M. Wessels, Autor ; Bruce G. Pollock, Autor ; Norbert G. Anyama, Autor . - 2022 . - pp. 683-687. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 683-687 Palabras clave: Enfermedad de Alzheimer, Suspensión del tratamiento, 9-OH risperidona Resumen: Risperidone has been used to treat behavioral symptoms, such as delusions and agitation, in people with Alzheimer's disease. The relationship between magnitude and variability of risperidone and 9-hydroxy risperidone exposure and the relationship with time to discontinuation of the medication were explored. Link: ./index.php?lvl=notice_display&id=29416

Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder / Gabriele Masi en Journal of Clinical Psychopharmacology, Año 2010 - Vol. 30 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 688-693 Título : Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder Tipo de documento: texto impreso Autores: Gabriele Masi, Autor ; Chiara Pfanner, Autor ; Stefania Millepiedi, Autor Fecha de publicación: 2022 Artículo en la página: pp. 688-693 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Aripiprazol, Trastorno obsesivo compulsivo, Adolescencia, Farmacoterapia, Aumento, Adolescencia Resumen: The aim of this study was to assess efficacy of aripiprazole augmentation of serotonin reuptake inhibitor (SRI) treatment in adolescents with obsessive-compulsive disorder (OCD) who did not respond to 2 initial trials with SRI monotherapy. Link: ./index.php?lvl=notice_display&id=29417 [artículo] Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder [texto impreso] / Gabriele Masi, Autor ; Chiara Pfanner, Autor ; Stefania Millepiedi, Autor . - 2022 . - pp. 688-693. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 688-693 Palabras clave: Aripiprazol, Trastorno obsesivo compulsivo, Adolescencia, Farmacoterapia, Aumento, Adolescencia Resumen: The aim of this study was to assess efficacy of aripiprazole augmentation of serotonin reuptake inhibitor (SRI) treatment in adolescents with obsessive-compulsive disorder (OCD) who did not respond to 2 initial trials with SRI monotherapy. Link: ./index.php?lvl=notice_display&id=29417

Next-day residual sedative effect after nighttime administration of an over-the-counter antihistamine sleep aid, diphenhydramine, measured by positron emission tomography / Dongying Zhang en Journal of Clinical Psychopharmacology, Año 2010 - Vol. 30 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 694-701 Título : Next-day residual sedative effect after nighttime administration of an over-the-counter antihistamine sleep aid, diphenhydramine, measured by positron emission tomography Tipo de documento: texto impreso Autores: Dongying Zhang, Autor ; Manabu Tashiro, Autor ; Katsuhiko Shibuya, Autor Fecha de publicación: 2022 Artículo en la página: pp. 694-701 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Efecto sedante residual, Difenhidramina, Bepotastina, Ocupación del receptor H1 de histamina, Tomografía por emisión de positrones, Somnífero de venta libre, Estudio cruzado Resumen: Antihistamines often are self-administered at night as over-the-counter (OTC) sleep aids, but their next-day residual sedative effect has never been evaluated using a reliable quantitative method such as positron emission tomography (PET). Link: ./index.php?lvl=notice_display&id=29418 [artículo] Next-day residual sedative effect after nighttime administration of an over-the-counter antihistamine sleep aid, diphenhydramine, measured by positron emission tomography [texto impreso] / Dongying Zhang, Autor ; Manabu Tashiro, Autor ; Katsuhiko Shibuya, Autor . - 2022 . - pp. 694-701. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 694-701 Palabras clave: Efecto sedante residual, Difenhidramina, Bepotastina, Ocupación del receptor H1 de histamina, Tomografía por emisión de positrones, Somnífero de venta libre, Estudio cruzado Resumen: Antihistamines often are self-administered at night as over-the-counter (OTC) sleep aids, but their next-day residual sedative effect has never been evaluated using a reliable quantitative method such as positron emission tomography (PET). Link: ./index.php?lvl=notice_display&id=29418